163 related articles for article (PubMed ID: 34250392)
1. Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
Koptiuch C; Espinel WF; Kohlmann WK; Zhao J; Kaphingst KA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250392
[TBL] [Abstract][Full Text] [Related]
2. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
[TBL] [Abstract][Full Text] [Related]
3. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
4. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.
Mohindroo C; De Jesus-Acosta A; Yurgelun MB; Maitra A; Mork M; McAllister F
Surg Pathol Clin; 2022 Sep; 15(3):491-502. PubMed ID: 36049831
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study.
Rodriguez NJ; Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Fortes I; Caruso A; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Zhou AY; Coffin TB; Uno H; Horiguchi M; Ocean AJ; McAllister F; Lowy AM; Klein AP; Madlensky L; Petersen GM; Garber JE; Lippman SM; Goggins MG; Maitra A; Syngal S
Gastroenterology; 2024 May; 166(5):872-885.e2. PubMed ID: 38320723
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
8. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Lafferty CC; Talcove-Berko ER; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Law S; Zhou AY; Coffin TB; Rodriguez NJ; Uno H; Ocean AJ; McAllister F; Lowy AM; Lippman SM; Klein AP; Madlensky L; Petersen GM; Garber JE; Goggins MG; Maitra A; Syngal S
Cancer Prev Res (Phila); 2021 Nov; 14(11):1021-1032. PubMed ID: 34625409
[TBL] [Abstract][Full Text] [Related]
9. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
Peters MLB; Stobie L; Dudley B; Karloski E; Allen K; Speare V; Dolinsky JS; Tian Y; DeLeonardis K; Krejdovsky J; Button A; Lim C; Borazanci E; Brand R; Tung N
Cancer; 2019 Jul; 125(14):2488-2496. PubMed ID: 30980401
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in Chinese ovarian cancer with or without breast cancer.
Kwong A; Ho CYS; Shin VY; Au CH; Luk WP; Fung LH; Chan TL; Chan KKL; Ngan HYS; Ma ESK
Mol Genet Genomic Med; 2022 Jul; 10(7):e1940. PubMed ID: 35608067
[TBL] [Abstract][Full Text] [Related]
12. Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.
Pozzar RA; Hong F; Xiong N; Stopfer JE; Nayak MM; Underhill-Blazey M
Fam Cancer; 2022 Jan; 21(1):35-47. PubMed ID: 33751319
[TBL] [Abstract][Full Text] [Related]
13. Inherited predisposition to pancreatic cancer.
Hilfrank KJ; Rustgi SD; Kastrinos F
Semin Oncol; 2021 Feb; 48(1):2-9. PubMed ID: 33773812
[TBL] [Abstract][Full Text] [Related]
14. Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
Mooney R; Espinel W; Elrick A; Kehoe K; Kohlmann W; Kaphingst KA
J Genet Couns; 2022 Apr; 31(2):470-478. PubMed ID: 34570943
[TBL] [Abstract][Full Text] [Related]
15. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
Drogan CM; Kindler HL; Gao G; Kupfer SS
JCO Precis Oncol; 2023 Jan; 7():e2200196. PubMed ID: 36689696
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
Hu C; Hart SN; Bamlet WR; Moore RM; Nandakumar K; Eckloff BW; Lee YK; Petersen GM; McWilliams RR; Couch FJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):207-11. PubMed ID: 26483394
[TBL] [Abstract][Full Text] [Related]
19. Identification of genetic risk for pancreatic adenocarcinoma.
Flores K; Dinh K; Rouleau E; Whalen G; Wassef W; LaFemina J
Cancer Genet; 2015 Nov; 208(11):559-63. PubMed ID: 26481832
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes.
Gardiner A; Kidd J; Elias MC; Young K; Mabey B; Taherian N; Cummings S; Malafa M; Rosenthal E; Permuth JB
J Natl Cancer Inst; 2022 Jul; 114(7):996-1002. PubMed ID: 35445726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
